ArticleFrontiers in pharmacology2026

Case Report: A patient harboring rare EGFR S768I/V769L compound mutation benefited from afatinib and osimertinib.

Qingli Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.